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IDF International Diabetes Foundation 
IFG Impaired fasting glucose 
IGT Impaired glucose tolerance 
IKK-β Inhibitor of nuclear factor kappa-B kinase beta 
IR Insulin resistance 
IRs Insulin receptors 
IST Insulin signal transduction 
KATP ATP-sensitive potassium channels 
Keap-1 Kelch-like ECH-associated protein 1 
LUTH Lagos University Teaching Hospital 
MG-H1 methylglyoxal-derived hydroimidazolone 1 
MPs Medicinal plants 
MS Mass spectroscopy 
NIMR National Institute of Medical Research 
NIST National Institute of Standards and Technology 
NL Nauclea latifolia 
NLR Neutrophil-to-lymphocyte ratio 
NOAEL No observed adverse effect level 
 xxi 
 
NSAIDS Non-steroidal anti-inflammatory drugs 
OECD Organization for Economic Cooperation and Development 
OGCT Oral glucose challenge test 
OGTT Oral glucose tolerance test 
PCR Polymerase chain reaction 
PlGF  Placenta growth factor 
pNPG ρ-Nitrophenyl-α-D-glucopyranoside 
PPARγ  Peroxisome proliferative-activated receptor gamma 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol 3,4,5-trisphosphate 
QUIKI Quantitative insulin-sensitivity check index 
RBC Red blood cells 
RE Rutin equivalent 
RO5 Lipinski rule of five 
ROS Reactive oxygen species 
RTg  Renal threshold for glucose 
RT-PCR Reverse transcriptase-polymerase chain reaction  
SGLT Sodium-glucose cotransporter 
SHBG  Sex hormone binding globulin 
STZ Streptozotocin 
T1DM Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
T3DM Type 3 diabetes mellitus 
TAC Total antioxidant activity 
TAE Tannic acid equivalent 
TC Terminalia catappa 
TFC Total flavonoid content 
TP Total protein 
TPC Total phenolic content 
TRIG Triglycerides 
TTC Total tannin content 
TZD Thiazolidinedione 





Nauclea latifolia (NL) and Terminalia catappa (TC) leaves are used by locals in Nigeria to 
treat diabetes. However, there is paucity of scientific data on the antidiabetic activities and 
molecular mechanisms of action of these plants; hence, the set objectives of this research 
work. Samples of NL and TC leaves were collected from Ibadan in Oyo State and Ota in 
Ogun State, respectively, and identified. Aqueous (A) and ethanol (E) crude extracts of the 
plants were prepared for the analyses. Phytochemical analyses, in silico simulation, in vitro 
antidiabetic and membrane stabilising assessments were carried out using standard 
methods. Phytoconstituent assessment of NL and TC leaves using gas chromatography-
mass spectroscopy (GC-MS) revealed the presence of 50 and 38 different phytochemicals, 
respectively. These were categorized as alcohols, alkaloids, carbohydrates, hydrocarbons, 
carboxylic acids, phenolics, fatty acids, terpenes/terpenoids and pyrethrin. The leaves 
possessed ferric-reducing power, total antioxidant activity, 2,2-diphenyl-1-picrylhydrazyl, 
hydrogen peroxide radical scavenging activities and membrane-stabilizing potential 
comparable with synthetic antioxidants such as butylated hydroxytoluene, ascorbic acid and 
ibuprofen. They also exhibited significant (p<0.05) inhibitory property on α-amylase and 
α-glucosidase with IC50 values comparable with acarbose. For the inhibitory kinetics, NL 
extracts (NLE and NLA) exhibited uncompetitive and competitive inhibition on α-
glucosidase and α-amylase, respectively, while TC extracts (TCA and TCE) exhibited a 
mixed inhibition on α-amylase. However, TCA and TCE exhibited non-competitive and 
mixed-mode of inhibition, respectively on α-glucosidase. TCA showed significantly 
(p<0.05) higher in vitro antidiabetic activity than the other extracts and was subjected to in 
vivo toxicological and antidiabetic evaluation. In acute toxicity studies, the LD50 of TCA 
was > 5000 mg/kg b.wt with no significant (p>0.05) changes in general behaviour and 
mortality. The sub-acute toxicological evaluation at the experimental doses revealed no 
significant (p>0.05) alteration in the weight, biochemical, haematological and 
histopathological indices of the experimental animals. The induction of diabetes in high-fat 
diet/low dose streptozotocin-induced diabetic rats led to a loss of weight, initiation of 
systemic and organ oxidative stress, plasma and organ dyslipidaemia, liver and kidney 
dysfunction as well as observed abnormal level in other diabetes-related parameters. Upon 
28-day repeated administration of TCA, these observed systemic and organ anomaly were 
significantly (p<0.05) reversed to levels that are comparable to glibenclamide 
administration. In silico studies of 18 compounds selected from GC-MS identified 
phytoconstituents of the plants revealed four compounds (n-hexadecanoic acid, vitamin E, 
ethyl-α-d-glucopyranoside and phytol) that were potent DPP-IV, α-glucosidase and α-
amylase inhibitors comparable to saxagliptin, alogliptin and acarbose. These four 
compounds also exhibited promising oral bioavailability, pharmacokinetics and toxicity 
profile. In conclusion, these plant extracts possess antidiabetic activities and do not elicit an 
adverse toxic effect at the doses tested. It also displays various mechanisms at which these 
plant extracts as well as their phytoconstituents elicit their antidiabetic action. Further 
studies are required to establish the antidiabetic potential and mechanism of action of ethyl-
α-d-glucopyranoside and novel bioactive compounds from N. latifolia and T. catappa 
leaves. 
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